Blood Pressure最新文献

{"title":"Electrocardiographic left ventricular hypertrophy in relation to peripheral and central blood pressure indices in a Nigerian population","authors":"A. Odili, B. Chori, B. Danladi, Wen‐Yi Yang, Zhenyu Zhang, L. Thijs, F. Wei, T. Nawrot, T. Kuznetsova, J. Staessen","doi":"10.1080/08037051.2019.1646610","DOIUrl":"https://doi.org/10.1080/08037051.2019.1646610","url":null,"abstract":"Abstract Purpose: Previous studies that addressed whether left ventricular hypertrophy is more closely associated with central than peripheral blood pressure (BP) have been inconsistent. Radial artery wave generated by applanation tonometry and calibrated with brachial BP in 162 adult Nigerians were analysed by using generalized transfer function to derive central BP. Materials and methods: We compared the associations of ECG voltages and left ventricular hypertrophy (ECG-LVH) as continuous and binary variables respectively with central and brachial BP indices. Results: In a multivariable adjusted analysis, 1 standard deviation (SD) increase in brachial systolic, diastolic, pulse and mean arterial pressures increased the Sokolow–Lyon QRS voltage by 0.34 (CI, 0.21–0.48; p < 0.0001), 0.21 (CI, 0.07–0.36; p < 0.05); 0.22 (CI, 0.9–0.34; p < 0.001) and 0.29 (CI, 0.14–0.43) similar to (p > 0.05) corresponding Sokolow–Lyon QRS increase of 0.26 (0.12–0.40, p < 0.001); 0.14 (0.00–0.28, p < 0.05); 0.24 (0.11–0.39; p < 0.001) and 0.19 (0.05–0.34, p < 0.05) respectively observed for 1 SD increment in central pressures. The odds ratio (OR) relating ECG-LVH to 1 SD increase in brachial systolic, pulse, and mean arterial pressures were 2.62 (CI, 1.49–4.65, p < 0.001); 1.88 (CI, 1.19–2.95, p < 0.01) and 2.16 (CI, 1.22–3.82, p < 0.01) was similar to (p > 0.05) corresponding OR of 2.41 (1.33–4.36, p < 0.01); 2.04 (1.23–3.37, p < 0.01); 2.00 (1.11–3.63, p < 0.001) observed for I SD increment in central pressures. Conclusion: Central and peripheral BP are similarly associated with Sokolow–Lyon ECG voltage and hypertrophy.","PeriodicalId":55591,"journal":{"name":"Blood Pressure","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2019-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08037051.2019.1646610","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48738094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of pulsed electromagnetic field therapy on blood pressure and circulating nitric oxide levels: a double blind, randomized study in subjects with metabolic syndrome","authors":"Chul-Ho Kim, C. Wheatley-Guy, G. Stewart, Dongwook Yeo, W. Shen, Bruce D. Johnson","doi":"10.1080/08037051.2019.1649591","DOIUrl":"https://doi.org/10.1080/08037051.2019.1649591","url":null,"abstract":"Abstract Purpose: Regulation of blood pressure (BP) is important in reducing the risk for cardiovascular disease. There is growing interest in non-pharmacological methods to treat BP including a novel approach using pulsed electromagnetic field therapy (PEMF). PEMF therapy has been proposed to impact physiological function at the cellular and tissue level and one possible mechanism is through an impact on endothelial function and nitric oxide (NO) related pathways. The focus of the present study was to evaluate the effect of PEMF on BP and NO in subjects with mild to moderate metabolic syndrome. Materials and methods: For 12 weeks, 23 subjects underwent PEMF therapy and 21 subjects underwent sham therapy. BP was measured at rest and near the end of submaximal exercise pre- and 12 week post-therapy. Additionally, plasma NO was measured at similar time points. Results: The PEMF demonstrated an increase in NO after therapy (p = .04) but SHAM did not (p = .37). For resting BP, there were no differences in systolic BP (SBP), diastolic BP (DBP) or mean arterial pressure (MAP) between groups (p > .05). During exercise, PEMF had a reduction in peak SBP (p = .04), but not SHAM (p = .57). PEMF demonstrated significant relationships between baseline SBP and change in SBP following therapy (r = −0.71, p < .01) and between MAP and change in MAP following therapy (r = −0.60, p < .01), but no such relationships were found in SHAM. Subjects with resting hypertension (SBP ≥140 mmHg) in PEMF (n = 11) had significant reductions in SBP, DBP and MAP when compared to SHAM with hypertension (n = 9) (p < .05). In this sub-group analysis, PEMF demonstrated lowered peak SBP (p = .04) at a given exercise load (p = .40) but SHAM did not (p > .05). Conclusion: PEMF may increase plasma NO availability and improve BP at rest and during exercise. However, this beneficial effect appears to be more pronounced in subjects with existing hypertension.","PeriodicalId":55591,"journal":{"name":"Blood Pressure","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08037051.2019.1649591","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"59547511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In memoriam: Alberto Zanchetti","authors":"Sverre E. Kjeldsen, Krzysztof Narkiewicz, Michel Burnier, Suzanne Oparil","doi":"10.1080/08037051.2018.1464383","DOIUrl":"https://doi.org/10.1080/08037051.2018.1464383","url":null,"abstract":"","PeriodicalId":55591,"journal":{"name":"Blood Pressure","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2018-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08037051.2018.1464383","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43739506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: “Polymorphisms of three genes (ACE, AGT and CYP11B2) in the renin–angiotensin–aldosterone system are not associated with blood pressure salt sensitivity: a systematic meta-analysis”","authors":"Justine R. Horne, C. O'connor, J. Madill, Sylvia Rinaldi, J. Gilliland","doi":"10.1080/08037051.2016.1270164","DOIUrl":"https://doi.org/10.1080/08037051.2016.1270164","url":null,"abstract":"We read with interest the article recently published in Blood Pressure by J. Sun and colleagues.[1] The authors conducted a meta-analysis of the literature investigating genetic variations in ACE (I/D), AGT (M235T) and CYP11B2 (C344T) with salt-sensitive hypertension. According to the title and conclusions of the paper, the authors conclude that these genetic variants are not associated with salt-sensitive hypertension. However, notable limitations in the design of their study preclude making this conclusion. The main limitation is that the authors did not consider other studies that examined genetic variants that are in strong linkage disequilibrium (LD) with the 3 markers of interest and they did not identify this as a limitation in their discussion. For example, ACE I/D is in complete LD with ACE rs4343 and studies that report either of these two variants are examining essentially the same variant.[2–4] Other examples include AGT (M235T) which is in strong LD with AGT A(-6)G [5] and CYP11B2 (C344T), which is in complete LD with CYP11B2 at rs28491316 [6]. Because of this oversight, the authors failed to identify several studies. One study that was omitted was completed by Iwai et al., which found an association between the C344T variant in CYP11B2, which is in complete LD with CYP11B2 rs28491316 and salt-sensitive hypertension.[6,7] To ensure that all biologically relevant studies are included in the meta-analysis, the search terms should have included SNPs that are in complete or strong (>80%) LD with the three variants of interest in order to assess all relevant literature to appropriately and adequately address the research question. Furthermore, there was no discussion detailing the reason for excluding randomized controlled trials (RCTs), or how the exclusion of such studies may have impacted the conclusion. As RCTs did not meet the inclusion criteria, several robust studies were disregarded including a randomized, double-blinded, placebocontrolled Latin-square trial, which found a significant link between salt-sensitive hypertension and the AGT gene at M235T.[8] An additional limitation is that only one study that did not meet the inclusion criteria was cited and discussed. That study also found no significant association between the three variants of interest and blood pressure salt sensitivity.[2] However, the authors failed to discuss other opposing studies, which did find that the variants of interest affected blood pressure salt sensitivity.[8] Given the main limitation of omitting highly relevant studies, which could alter the conclusions drawn, the authors should consider updating their methods and analysis to include all relevant studies.","PeriodicalId":55591,"journal":{"name":"Blood Pressure","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2017-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08037051.2016.1270164","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48672790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypertension and functional capacities in community-dwelling older women: a cross-sectional study","authors":"Hélio José Coelho Junior, B. Rodrigues, S. Aguiar, I. O. Gonçalves, F. Pires, R. Y. Asano, M. Uchida","doi":"10.1080/08037051.2016.1270163","DOIUrl":"https://doi.org/10.1080/08037051.2016.1270163","url":null,"abstract":"Abstract Purpose: The present study aimed to investigate the association between hypertension and physical/functional capacities in community-dwelling older females. Materials and methods: Older female volunteers were dichotomized in two groups: hypertensive (n = 134) and normotensive (n = 244). Volunteers had their medical records reviewed and underwent evaluations of anthropometric data (weight, height and body mass index) and of physical and functional capacities. Results: The results showed that hypertensive older females presented higher values for age, weight, body mass index, and resting diastolic blood pressure than normotensive older females. Normotensive older females showed a higher performance in the one-leg stand test and six-minute walk test compared with hypertensive older females. Age, body mass index, maximal walking speed, performance in the Time Up and Go and six-minute walk test, and diagnosis of diabetes mellitus type II were factors associated with hypertension using the chi-square test. However, the multivariate regression analysis indicated that performance in the six-minute walk test was the only factor associated with hypertension. Conclusions: The patients with higher scores in the six-minute walk test, which is associated with aerobic capacity, show less odds to have clinical diagnosis of hypertension. However, hypertension was not associated with poor physical and functional capacity.","PeriodicalId":55591,"journal":{"name":"Blood Pressure","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2017-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08037051.2016.1270163","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42085608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study","authors":"C. Mancusi, E. Gerdts, G. de Simone, H. Midtbø, M. T. Lønnebakken, K. Boman, K. Wachtell, B. Dahlöf, R. Devereux","doi":"10.1080/08037051.2016.1243009","DOIUrl":"https://doi.org/10.1080/08037051.2016.1243009","url":null,"abstract":"Abstract We tested the prognostic impact of a marker of arterial stiffness, pulse pressure/stroke volume index (PP/SVi), in patients with hypertension and left ventricular (LV) hypertrophy. We used data from 866 patients randomized to losartan or atenolol-based antihypertensive treatment, over a median of 4.8 years, in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. The association of PP/SVi with outcomes was tested in Cox regression analyses and reported as hazard ratio (HR) and 95% confidence intervals (CI). In multivariate regression, reduction of PP/SVi was independently associated with male gender, reduction in systolic blood pressure (BP) and relative wall thickness and with an increase in left ventricular ejection fraction (all p < .05). After adjusting for confounders, higher baseline PP/SVi predicted a 38% higher hazard of combined major fatal and non-fatal cardiovascular events (95% CI 1.04–1.84), and higher hazard of cardiovascular mortality (HR 2.35 (95% CI 1.59–3.48) and stroke (HR 1.45 (95% CI 1.06–1.99) (all p < .05). Higher PP/SVi also predicts higher rate of hospitalization for HF (HR 2.15 (95% CI 1.48–3.12) and a 52% higher hazard of all-cause mortality (95% CI 1.10–2.09) (both p < .05). In hypertensive patients with electrocardiographic LV hypertrophy, higher PP/SVi was associated with increased cardiovascular morbidity and mortality.","PeriodicalId":55591,"journal":{"name":"Blood Pressure","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2017-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08037051.2016.1243009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44100376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obituary","authors":"P. Verdecchia, G. de Simone","doi":"10.1080/08037051.2017.1280372","DOIUrl":"https://doi.org/10.1080/08037051.2017.1280372","url":null,"abstract":"Professor Giuseppe Schillaci passed away peacefully on 21 December 2016 at his home in Perugia at the early age of 55, after a four-year battle against lung cancer. Giuseppe was born on 27 September 1961. He was educated at the University of Palermo, Sicily, where he graduated in Medicine and Surgery in year 1985. In year 1990 he was appointed as Specialist in Internal Medicine in that University. In the same year he moved from Sicily to Umbria and joined our staff in the Hospital of Citt a della Pieve in Umbria, Central Italy. Throughout the next ten years Giuseppe worked on several research topics related mostly to hypertension and cardiovascular disease prevention. It was very much fun working with him. Giuseppe actively contributed to build the “Progetto Ipertensione Umbria Monitoraggio Ambulatoriale” (PIUMA), a longitudinal study in initially untreated hypertensive patients who underwent 24-h ambulatory blood pressure monitoring. In year 1994, using the PIUMA database, Giuseppe ideated and developed the “Perugia score”, a new electrocardiographic score for diagnosis of left ventricular hypertrophy in hypertensive patients [1]. Several studies conducted in independent laboratories confirmed the ability of the Perugia score to improve the sensitivity of electrocardiography for detection of left ventricular hypertrophy, without depressing specificity. In a subsequent study from our group, the Perugia score showed the highest population attributable risk for major cardiovascular events when compared to traditional electrocardiographic markers of left ventricular hypertrophy [2]. Giuseppe co-authored in the same year the first pivotal study showing the prognostic value of fully automated ambulatory blood pressure monitoring in hypertensive patients [3]. He also authored the first study strongly supporting the prognostic impact of diastolic dysfunction in hypertensive patients [4]. It is impossible to pick the most influential among the many scientific contributions that Giuseppe developed over the last two decades. Our group enormously benefitted from Giuseppe’s enthusiastic, dedicated and extremely dynamic output. He had the ability to hold and finalize multiple research projects with high competence and enthusiasm. In year 1998 Giuseppe moved to the University of Perugia, where he rapidly progressed from Researcher to Associate Professor of Medicine. In year 2011 he was appointed Director of Medicine in Terni. We remained in close contact and it was nice to see his expertise evolving toward other aspects of Cardiovascular Medicine including arterial structure and physiology. Among his numerous engagements, Giuseppe served several scientific societies including the Association for Research into Arterial Structure and Physiology (ARTERY), the Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) and the Societ a Italiana dell’Ipertensione Arteriosa (SIIA). Overall, Giuseppe authored or co-authored more than 300 full length papers, achievin","PeriodicalId":55591,"journal":{"name":"Blood Pressure","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2017-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08037051.2017.1280372","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42427554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endothelin-receptor antagonist can reduce blood pressure in patients with hypertension: a meta-analysis","authors":"W. Yuan, Genyang Cheng, Bin Li, Yansheng Li, Shan Lu, Dong Liu, Jing Xiao, Zhanzheng Zhao","doi":"10.1080/08037051.2016.1208730","DOIUrl":"https://doi.org/10.1080/08037051.2016.1208730","url":null,"abstract":"Abstract The aim of this meta-analysis was to assess the effectiveness and safety of endothelin-receptor antagonist (ERA) in the patients with hypertension. Searches of the PubMed, EMBASE, and CENTRAL databases were conducted to include all the randomized control trials (RCTs). Eighteen trials including 4898 patients were used in the meta-analysis, of which nine were classified as low risk of bias and the other nine as unclear risk of bias. There was no statistically significant difference in all-cause mortality between ERA and placebo groups [6 trials, fixed effects model, RR 1.53 (0.89–2.62); random effects model, RR 1.45 (0.84–2.52)]. ERA significantly reduced 24-h ambulatory blood pressure and sitting blood pressure in patients with hypertension [5 trials, 24-h SBP: WMD −7.65 (−8.95 to −6.36), 24-h DBP: WMD −5.92 (−7.50 to −4.33); 18 trials, SBP: WMD −6.12 (−7.87 to −4.36), DBP: WMD −3.81 (−4.82 to −2.80)]. However, ERA had more adverse events [within 24 h: 3 trials, RR 1.16 (0.82–1.65); after 24 h, 13 trials, RR 1.21 (1.08–1.36)] and severe adverse events than placebo controls [SAE: 9 trials, RR 1.34 (1.13–1.60)]. In addition, there is a potential need for further RCTs that focus on the use of ERA in patients with hypertension.","PeriodicalId":55591,"journal":{"name":"Blood Pressure","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2017-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08037051.2016.1208730","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48584611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between abnormal P-wave terminal force in lead V₁ and left ventricular diastolic dysfunction in hypertensive patients: the LIFE study.","authors":"Michael T Tanoue,&nbsp;Sverre E Kjeldsen,&nbsp;Richard B Devereux,&nbsp;Peter M Okin","doi":"10.1080/08037051.2016.1215765","DOIUrl":"https://doi.org/10.1080/08037051.2016.1215765","url":null,"abstract":"<p><strong>Background: </strong>Abnormal P-wave terminal force in lead V₁ (PTF-V₁) is an ECG marker of increased left atrial (LA) volume, elevated LA filling pressures and/or LA systolic dysfunction. Because left ventricular (LV) diastolic dysfunction is one of the potential mechanisms driving LA remodelling, we hypothesized that PTF-V₁ might be an additional ECG marker of diastolic dysfunction.</p><p><strong>Methods: </strong>LV diastolic function after 3 years' systematic antihypertensive treatment was examined in relation to baseline PTF-V₁ in 431 hypertensive patients undergoing protocol-driven blood pressure reduction who had baseline and year-3 ECG and echocardiographic data and a preserved LV ejection fraction (EF >45%) at year-3. Abnormal diastolic function was defined by the tenth or 90th percentile values from 405 normotensive, non-obese and non-diabetic adults without overt cardiovascular disease. Abnormal PTF-V_1, defined by the presence of a negative terminal P-wave in lead V1 ≥ 4000 μV·ms, was present in 167 patients (38.7%).</p><p><strong>Results: </strong>Abnormal PTF-V₁ was associated with worse year-3 mean diastolic first third filling time (0.43 ± 0.08 vs 0.40 ± 0.07 sec, p = 0.039), first half filling time (0.55 ± 0.07 vs 0.53 ± 0.07 sec, p = 0.041), mitral valve A velocity (86 ± 27 vs 76 ± 19 cm/sec, p = 0.009) and mitral valve E/A ratio (0.85 ± 0.22 vs 0.94 ± 0.27, p = 0.007) after adjusting for other potential predictors of diastolic dysfunction including race, and heart rate, systolic blood pressure and severity of ECG LVH by Cornell product criteria at baseline. In parallel multivariate logistic regression analysis, abnormal PTF-V₁ was associated with significantly increased odds of abnormal mitral valve E/A ratio (OR 1.55, 95%CI 1.04-2.32 p = 0.032), and a trend toward higher odds of abnormal half filling time (OR 1.42, 95%CI 0.94-2.15, p = 0.098) at year-3 of follow-up.</p><p><strong>Conclusions: </strong>Abnormal P-wave terminal force in lead V₁ is associated with worse diastolic function and predicts abnormal LV diastolic behaviour in patients with preserved EF after 3 years of blood pressure reductive therapy.</p>","PeriodicalId":55591,"journal":{"name":"Blood Pressure","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2017-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08037051.2016.1215765","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34367426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance of targeted screening for the identification of hypertension in children.","authors":"Clemens Bloetzer,&nbsp;Pascal Bovet,&nbsp;Fred Paccaud,&nbsp;Michel Burnier,&nbsp;Arnaud Chiolero","doi":"10.1080/08037051.2016.1213130","DOIUrl":"https://doi.org/10.1080/08037051.2016.1213130","url":null,"abstract":"<p><p>Targeted screening of hypertension in childhood might be more efficient than universal screening. We estimated the sensitivity, specificity, negative and positive predictive values of combined parental history of hypertension and overweight/obesity for the diagnosis of hypertension in 5207 children aged 10-14 years. Children had hypertension if they had sustained elevated blood pressure over three separate visits. The prevalence of hypertension was 2.2%. 14% of children were overweight or obese, 20% had a positive history of hypertension in at least one parent and 30% had either or both conditions. Targeted screening of hypertension to children with either overweight/obesity or with hypertensive parents limits the proportion of children (30%) to screen and identifies up to 65% of all hypertensive cases.</p>","PeriodicalId":55591,"journal":{"name":"Blood Pressure","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2017-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08037051.2016.1213130","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34368785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}